Lance Alstodt - Mar 18, 2022 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role: President, CEO, COB, Director
Signature: /s/ Lance Alstodt
Stock symbol: BRTX
Transactions as of: Mar 18, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/22/2022, 05:08 PM
Previous filing: Jan 24, 2022
Next filing: May 2, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BRTX	Common Stock	Award		+12.4K	+7.63%		176K	Mar 18, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BRTX	Stock Option						293K	Mar 18, 2022	Common Stock	293K	$13.50	Direct	F3
holding	BRTX	Stock Option						42.1K	Mar 18, 2022	Common Stock	42.1K	$13.50	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares received pursuant to a restricted stock unit grant. Vests in twelve nearly equal monthly installments beginning April 18, 2022.
F2	Includes 110,264 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares beginning on April 18, 2022 and continuing monthly through September 18, 2022, 1,036 shares beginning on October 18, 2022 and continuing monthly through February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
F3	The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 with the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F4	The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.